3.07
price up icon19.69%   0.505
 
loading

Synaptogenix Inc (SNPX) 最新ニュース

pulisher
Dec 21, 2024

Synaptogenix forms committee to explore strategic opportunities - Investing.com

Dec 21, 2024
pulisher
Dec 20, 2024

Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks

Dec 20, 2024
pulisher
Dec 20, 2024

Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan

Dec 20, 2024
pulisher
Dec 07, 2024

Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India

Dec 07, 2024
pulisher
Dec 07, 2024

Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada

Dec 07, 2024
pulisher
Nov 13, 2024

Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com

Nov 13, 2024
pulisher
Nov 05, 2024

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN

Nov 05, 2024
pulisher
Oct 15, 2024

Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World

Oct 15, 2024
pulisher
Oct 05, 2024

Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com

Oct 05, 2024
pulisher
Oct 04, 2024

Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Sep 24, 2024

Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com

Sep 24, 2024
pulisher
Sep 14, 2024

Synaptogenix announces new preferred stock series - Investing.com

Sep 14, 2024
pulisher
Sep 11, 2024

Synaptogenix Announces $5.0 Million Financing - citybiz

Sep 11, 2024
pulisher
Sep 11, 2024

Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India

Sep 11, 2024
pulisher
Sep 11, 2024

Synaptogenix secures $5 million in preferred stock financing - Investing.com India

Sep 11, 2024
pulisher
Sep 11, 2024

Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World

Sep 11, 2024
pulisher
Sep 10, 2024

Synaptogenix extends preferred shares maturity date - Investing.com

Sep 10, 2024
pulisher
Sep 02, 2024

Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Sep 02, 2024
pulisher
Aug 30, 2024

Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews

Aug 30, 2024
pulisher
Aug 18, 2024

SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 16, 2024

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace

Aug 16, 2024
pulisher
Aug 09, 2024

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Aug 09, 2024
pulisher
Aug 01, 2024

Synaptogenix - The Pharma Letter

Aug 01, 2024
pulisher
Jul 26, 2024

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga

Jul 26, 2024
pulisher
Jul 26, 2024

Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga

Jul 26, 2024
pulisher
Jul 19, 2024

New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter

Jul 19, 2024
pulisher
Jul 19, 2024

Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online

Jul 19, 2024
pulisher
Jul 19, 2024

Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary - Benzinga

Jul 19, 2024
pulisher
Jul 18, 2024

Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com

Jul 18, 2024
pulisher
Jul 18, 2024

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - Lelezard

Jul 18, 2024
pulisher
Jul 12, 2024

Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga

Jul 12, 2024
pulisher
Jul 12, 2024

Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to “Buy” - Defense World

Jul 12, 2024
pulisher
Jul 09, 2024

Synaptogenix (NASDAQ:SNPX) Trading Down 0.5% - Defense World

Jul 09, 2024
pulisher
Jul 03, 2024

Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today

Jul 03, 2024
pulisher
Jun 30, 2024

Synaptogenix Acquires 25% Stake In Cannasoul - Quantisnow

Jun 30, 2024
pulisher
Jun 27, 2024

FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Yahoo Finance

Jun 27, 2024
pulisher
Jun 27, 2024

FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena

Jun 27, 2024
pulisher
Jun 26, 2024

Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Australia

Jun 26, 2024
pulisher
Jun 26, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 26, 2024
pulisher
Jun 26, 2024

Dana Incorporated names Lisa Amend as new HR Chief By Investing.com - Investing.com South Africa

Jun 26, 2024
pulisher
Jun 26, 2024

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - StockTitan

Jun 26, 2024
pulisher
Jun 21, 2024

Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024TipRanks.com - TipRanks

Jun 21, 2024
pulisher
Apr 23, 2024

Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga

Apr 23, 2024
pulisher
Apr 10, 2024

Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report

Apr 10, 2024
pulisher
Apr 03, 2024

Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa

Apr 03, 2024
pulisher
Feb 22, 2024

Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider

Feb 22, 2024
pulisher
Jan 31, 2024

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider

Jan 31, 2024
pulisher
Dec 23, 2023

Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga

Dec 23, 2023
pulisher
Dec 19, 2023

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire

Dec 19, 2023
pulisher
Nov 02, 2023

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire

Nov 02, 2023
pulisher
Nov 01, 2023

Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million. - Marketscreener.com

Nov 01, 2023
pulisher
Oct 16, 2023

'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com

Oct 16, 2023
pulisher
Oct 06, 2023

Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today

Oct 06, 2023
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):